JSA Advocates & Solicitors advised Forus Health Private Limited (“Forus”) and its Co-founder & CEO in a secondary transaction involving the acquisition of a 21% stake in Forus by Inviga Healthcare Fund (“Inviga”).
Forus is a leading ophthalmic technology company renowned for its 3nethra series of eye screening devices that have screened over 22 million patients across 75 countries. Leveraging AI-driven diagnostics, its platform has served over 5 million patients worldwide, advancing early detection and accessibility in eye care. The company’s latest innovation, the 3nethra specto — a smartphone-controlled wearable digital refractor — is redefining tele-optometry and remote vision screening. Forus was recently recognised among TIME Magazine’s World’s Top 400 HealthTech Companies for its contribution to global vision care.
Inviga is developing a differentiated multi-specialty hospital platform while strategically investing in high-potential healthcare and life sciences ventures. Through its dual-track strategy of majority-led hospital roll-ups and minority investments in innovative, IP-driven enterprises, Inviga aims to accelerate scalable healthcare solutions and long-term value creation across the ecosystem.
JSA acted as the legal advisor to Forus Health and its Co-founder & CEO on this transaction.
The JSA Corporate Team comprised Partner Manuel Jose and Senior Associate Harshita Agarwal.
Manuel’s practice focuses primarily on corporate transactional matters such as cross-border acquisitions, joint ventures, strategic alliances, private equity and venture capital investments, business re-organizations or transfers, and other corporate acquisitions and exits.